Scientists have developed a novel peptide that could potentially revolutionize the treatment of Alzheimer's disease and other neurodegenerative disorders known as tauopathies.
The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized ...
A peptide inhibitor called RI-AG03 targets major aggregation “hot spots” of tau proteins, believed to be a key driver of ...
ScienceAlert on MSN2d
Breakthrough Alzheimer's Drug Targets Key 'Hotspots' to Suppress Toxic TanglesThe drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...
An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease. For the first time, scientists have developed a drug that works on ...
AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.
Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...
Dr Anthony Aggidis, a former Postdoctoral Research Associate at Lancaster University, led the study of the drug RI-AG03.
A team of researchers has reported a significant advance in Alzheimer’s treatment. Their candidate drug, RI-AG03, attacks the accumulation of tau proteins—crucial to the disease’s progression—in lab ...
6don MSN
An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback